CN117987333B - Composite probiotics for relieving sports fatigue and application thereof - Google Patents
Composite probiotics for relieving sports fatigue and application thereof Download PDFInfo
- Publication number
- CN117987333B CN117987333B CN202410405247.5A CN202410405247A CN117987333B CN 117987333 B CN117987333 B CN 117987333B CN 202410405247 A CN202410405247 A CN 202410405247A CN 117987333 B CN117987333 B CN 117987333B
- Authority
- CN
- China
- Prior art keywords
- strain
- probiotic
- fatigue
- group
- rats
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 63
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 62
- 239000002131 composite material Substances 0.000 title description 10
- 241000191998 Pediococcus acidilactici Species 0.000 claims abstract description 8
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 7
- 230000000529 probiotic effect Effects 0.000 claims description 34
- 238000004321 preservation Methods 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- -1 pH regulator Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 230000013777 protein digestion Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 241001495180 Arthrospira Species 0.000 claims description 2
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 241000222355 Trametes versicolor Species 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940082787 spirulina Drugs 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 102000004169 proteins and genes Human genes 0.000 abstract description 25
- 108090000623 proteins and genes Proteins 0.000 abstract description 25
- 235000019621 digestibility Nutrition 0.000 abstract description 10
- 102000057297 Pepsin A Human genes 0.000 abstract description 9
- 108090000284 Pepsin A Proteins 0.000 abstract description 9
- 229940111202 pepsin Drugs 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 230000004792 oxidative damage Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 24
- 239000000047 product Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 229920002527 Glycogen Polymers 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 229940096919 glycogen Drugs 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 102000004420 Creatine Kinase Human genes 0.000 description 7
- 108010042126 Creatine kinase Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 108010046334 Urease Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000037149 energy metabolism Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052564 epsomite Inorganic materials 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000007696 Kjeldahl method Methods 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000006609 metabolic stress Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- SFAYBQDGCKZKMH-UHFFFAOYSA-N BNCC Chemical compound BNCC SFAYBQDGCKZKMH-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a compound probiotics for relieving sports fatigue and application thereof, wherein the compound probiotics for relieving sports fatigue consists of Pediococcus acidilactici ACIDILACTICI PA strain and Bifidobacterium longum Bifidobacterium longum BL strain. The PA53 strain and the BL21 strain are combined, and the PA53 strain and the BL21 strain can be matched with each other, promote each other and synergistically increase in the aspect of relieving sports fatigue, and are specifically expressed in: the protein digestibility and the pepsin activity are obviously improved; improving physical exercise fatigue; significantly reducing oxidative damage.
Description
Technical Field
The invention belongs to the technical field of probiotics, and relates to a compound probiotic for relieving sports fatigue and application thereof.
Background
Fatigue may lead to symptoms such as insufficient sleep, reduced memory, lack of energy, inattention, reduced work efficiency and mobility. Digestion, absorption and metabolism of proteins play a key role in maintaining physical health and energy balance. Proteins are the basic components that make up muscles, enzymes, hormones and many key molecules. Proper protein digestion and absorption is critical for muscle repair, growth, and overall health. However, poor protein metabolism may lead to energy shortages, muscle fatigue and overall health decline. Therefore, the search for natural anti-fatigue agents without side effects is an important research direction. Probiotics, a natural anti-fatigue agent, have potential roles in regulating intestinal flora balance, improving intestinal health, and affecting overall health and energy metabolism through the gut-brain axis. However, there are relatively few reports in the prior art on probiotic products with exercise fatigue relieving effects, so that it is very necessary to develop a probiotic product with exercise fatigue relieving effects.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a composite probiotic for relieving sports fatigue and application thereof, in particular to a composite probiotic for relieving sports fatigue and application thereof in preparing foods, health care products or medicines for preventing and/or relieving sports fatigue and in preparing products for improving protein digestion or absorption capacity.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
In a first aspect, the invention provides a compound probiotic for relieving sports fatigue, which consists of Pediococcus acidilactici ACIDILACTICI PA strain with the preservation number of CGMCC No. 18798 and bifidobacterium longum Bifidobacterium longum BL strain with the preservation number of CGMCC No. 10452.
The invention creatively develops a brand-new probiotic compound mode and a brand-new strategy for relieving sports fatigue, namely the Pediococcus acidilactici ACIDILACTICI PA strain and the Bifidobacterium longum Bifidobacterium longum BL strain are compounded and combined, and the two strains are found to be matched with each other, mutually promote and synergistically improve the sports fatigue relieving aspect, and the invention is specifically characterized in that: (1) The protein digestibility and the pepsin activity are obviously improved; (2) improving physical exercise fatigue; (3) significantly reducing oxidative damage.
Under the condition of consistent bacterial load, compared with the intervention mode of a single PA53 strain or a single BL21 strain, the effect of the combination of the two bacteria on the aspect of relieving sports fatigue is obviously improved. Therefore, the composite probiotics have good prospect in preparing foods, health care products or medicines for preventing and/or relieving sports fatigue. Meanwhile, both bacteria are probiotics, the product safety is high, and the resistance is not easy to generate.
The preparation method of the composite probiotics adopts a technical method conventional in the field, and can be exemplified by: activating the PA53 strain or the BL21 strain, and then respectively inoculating the activated PA53 strain or BL21 strain into a culture medium for culture to obtain a culture solution; centrifuging the culture solution, and re-suspending the bacteria to obtain bacterial suspension; mixing the two bacterial suspensions according to the ratio of the viable bacteria number. Or further adding a protective agent for freeze drying to obtain a freeze-dried bacterial powder product.
Preferably, the ratio of the viable count of the PA53 strain to the viable count of the BL21 strain is 1:50-50:1, for example 1:50、1:40、1:35、1:25、1:20、1:18、1:15、1:12、1:10、1:9、1:8、1:7、1:6、1:5、1:4、1:3、1:2、1:1、2:1、3:1、4:1、5:1、6:1、7:1、8:1、9:1、10:1、12:1、15:1、18:1、20:1、25:1、30:1、40:1、50:1, and other specific values within the numerical range are selectable, which will not be described in detail herein.
In a second aspect, the invention provides a probiotic for preventing sports fatigue, wherein the strain in the probiotic comprises the composite probiotic of the first aspect.
Preferably, in the probiotic agent, the total number of viable bacteria is not lower than 5×10 9 CFU/mL or 5×10 9 CFU/g, for example 5×109 CFU/g（CFU/mL）、1×1010 CFU/g（CFU/mL）、2×1010 CFU/g（CFU/mL）、5×1010 CFU/g（CFU/mL）、8×1010 CFU/g（CFU/mL）、1×1011 CFU/g（CFU/mL）、5×1011 CFU/g（CFU/mL）、1×1012 CFU/g（CFU/mL）、1×1013 CFU/g（CFU/mL）、1×1014 CFU/g（CFU/mL）, and other specific values within the numerical range can be selected, which will not be described in detail herein.
Preferably, the probiotic agent further comprises a lyoprotectant.
The freeze-drying protective agent comprises any one or a combination of at least two of skim milk, gelatin, dextrin, acacia, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.
Preferably, the probiotic agent further comprises an auxiliary additive.
The auxiliary additive comprises any one or a combination of at least two of fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, soybean oligosaccharide, inulin, spirulina, arthrospira, coriolus versicolor polysaccharide, stachyose, polydextrose, alpha-lactalbumin or lactoferrin.
Preferably, the formulation of the probiotic agent comprises freeze-dried powder, capsules, tablets or granules.
The formulation of the probiotics related to the invention is not limited, and comprises the most commonly used freeze-dried powder, or further prepared capsules, tablets or granules. The lyophilized powder can be prepared by the following method:
Activating the PA53 strain and the BL21 strain, and then respectively inoculating the PA53 strain and the BL21 strain into a culture medium for culture to obtain a culture solution; centrifuging the culture solution to obtain thalli; re-suspending the thalli by using a freeze-drying protective agent to obtain re-suspension; freeze-drying the heavy suspension, and mixing according to a proportion to obtain the finished product.
Preferably, the medium includes an MRS medium.
Preferably, the MRS medium includes, in concentration: 8-12 g/L of peptone, 8-12 g/L of beef extract, 15-25 g/L of glucose, 10-20 g/L of lactose, 3-7 g/L of yeast powder, 1-3 g/L、K2PO4·3H2O 2-3 g/L、MgSO4·7H2O 0.05-0.2 g/L、MnSO4 0.01-0.1 g/L、 Tween 80 0.5-2 mL/L of diammonium hydrogen citrate and 0.1-1 g/L of cysteine hydrochloride.
Preferably, the lyophilization is by vacuum freezing.
In a third aspect, the invention provides the use of a composite probiotic according to the first aspect or a probiotic according to the second aspect in the manufacture of a food, health product or pharmaceutical product for preventing and/or alleviating sports fatigue.
Preferably, the product further comprises auxiliary materials.
The auxiliary materials are selected from any one or a combination of at least two of filler, adhesive, wetting agent, disintegrating agent, emulsifying agent, cosolvent, solubilizer, osmotic pressure regulator, colorant, pH regulator, antioxidant, antibacterial agent or buffering agent.
In a fourth aspect, the present invention also provides the use of a complex probiotic according to the first aspect or a probiotic according to the second aspect for the preparation of a product for improving the digestion or absorption capacity of a protein.
Compared with the prior art, the invention has the following beneficial effects:
The invention creatively develops a brand-new probiotic compound mode and a brand-new strategy for relieving sports fatigue, namely the Pediococcus acidilactici ACIDILACTICI PA strain and the Bifidobacterium longum Bifidobacterium longum BL strain are compounded and combined, and the two strains can be matched with each other, mutually promote each other and synergistically improve the sports fatigue relieving aspect. Under the condition of consistent bacterial load, compared with the intervention mode of a single PA53 strain or a single BL21 strain, the effect of the combination of the two bacteria on the aspect of relieving sports fatigue is obviously improved. Therefore, the composite probiotics have good prospect in preparing foods, health care products or medicines for preventing and/or relieving sports fatigue. Meanwhile, both bacteria are probiotics, the product safety is high, and the resistance is not easy to generate.
The PA53 strain related by the invention is classified and named as Pediococcus acidilactici Pediococcus acidilactici, the preservation unit is China general microbiological culture Collection center, the preservation time is 2019, 11 months and 04 days, the preservation number is CGMCC No. 18798, and the address is: the korean district North Star, beijing city, part No. 1, no. 3.
The BL21 strain related by the invention is classified and named as bifidobacterium longum Bifidobacterium longum, the preservation unit is China general microbiological culture Collection center, the preservation time is 2015, 01 and 27 days, the preservation number is CGMCC No. 10452, and the address is: the korean district North Star, beijing city, part No. 1, no. 3.
Drawings
FIG. 1 is a graph showing the results of protein digestibility statistics for each group of rats;
FIG. 2 is a graph showing the results of pepsin activity statistics for each group of rats;
FIG. 3 is a graph of swimming time statistics for each group of rats;
FIG. 4 is a graph of statistical results of serum blood lactate levels for each group of rats;
FIG. 5 is a graph of statistical results of serum lactate dehydrogenase levels for various groups of rats;
FIG. 6 is a graph of statistical results of serum urease levels in various groups of rats;
FIG. 7 is a graph of statistical results of serum glucose levels for each group of rats;
FIG. 8 is a graph of statistical results of serum free fatty acid levels for each group of rats;
FIG. 9 is a graph showing the statistical results of serum creatine kinase activity in rats of each group;
FIG. 10 is a graph of the statistical results of liver glycogen levels in each group of rats;
FIG. 11 is a graph showing the statistical results of myoglycogen levels in each group of rats;
FIG. 12 is a graph showing the statistical results of the levels of active oxygen in serum of rats in each group;
FIG. 13 is a graph showing the statistical result of the active oxygen levels in gastrocnemius of rats of each group;
FIG. 14 is a graph of statistical results of malondialdehyde levels in serum from various groups of rats;
Figure 15 is a graph of statistical results of malondialdehyde levels in gastrocnemius muscle in rats of each group;
figure 16 is a graph of statistics of nitric oxide levels in gastrocnemius muscle of rats in each group.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
The PA53 strain according to the following examples is classified and named as pediococcus acidilactici Pediococcus acidilactici, the preservation unit is the China general microbiological culture Collection center, the preservation time is 2019, 11 and 04, the preservation number is CGMCC No. 18798, and the address is: the korean district North Star, beijing city, part No. 1, no. 3.
The BL21 strain related to the following examples is classified and named as Bifidobacterium longum Bifidobacterium longum, the preservation unit is China general microbiological culture Collection center, the preservation time is 2015, 01 and 27 days, the preservation number is CGMCC No. 10452, and the address is: the korean district North Star, beijing city, part No. 1, no. 3.
Peptone, beef extract, glucose, lactose, yeast powder, diammonium hydrogen citrate, K 2PO4·3H2O、MgSO4·7H2O、MnSO4, tween 80 and cysteine hydrochloride referred to in the examples below were purchased from the national pharmaceutical group chemical company.
The following examples relate to the following media:
MRS Medium (g/L): 10g/L of peptone, 10g/L of beef extract, 15g/L of glucose, 15g/L of lactose, 5g/L of yeast powder, 1mL/L of ammonium citrate 2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、 Tween 80 and 0.5g/L of cysteine amino acid salt.
The bacterial suspensions referred to in the following examples: inoculating the required strain into MRS liquid culture medium, culturing at 37deg.C for 24 hr for activation, and continuously activating for 2 times to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 37 ℃ for 24 hours to obtain bacterial solution; centrifuging the bacterial liquid at 6000g for 10min, and re-suspending the bacterial body by using PBS.
Statistical analysis of test result data using ggplot of R language, # represents p <0.001 compared to control group; compared to the model group, p <0.001, p <0.01, p <0.05, ns.
Examples
The influence of the compound probiotics on the sports fatigue rat model is explored in the embodiment:
(1) Test animals: male SD rats (180-220 g) (purchased from Shanghai Chengxi Biotechnology Co., ltd.) without specific pathogen, which were supplied with standard laboratory diet and water, and kept in SPF-class laboratories, maintained at room temperature 23.+ -. 1 ℃ and humidity 50%.+ -. 5%, following 12h light/dark cycle. All experimental procedures involving rats were in compliance with the ethical guidelines for animal care and use prescribed by the Shanghai laboratory animal Care and animal Experimental center.
(2) Grouping animals: after 1 week of adaptive feeding in the above rats, the rats were randomly divided into 7 groups (12 per group): control group (CTL group, 5.2 mg/g weight per day of gastric lavage protein powder), model group (MC group, 5.2 mg/g weight per day of gastric lavage protein powder), PA53 group (S1 group, 5.2 mg/g weight per day of gastric lavage protein powder+10 8 CFU/g weight of probiotics), BL21 group (S2 group, 5.2 mg/g weight per day of gastric lavage protein powder+10 8 CFU/g weight of probiotics), commercially available pediococcus acidilactici strain BNCC192198 group (S3 group, 5.2 mg/g weight per day of gastric lavage protein powder+10 8 CFU/g weight of probiotics), complex bacterium group 1 (PA 53+bl21 group, ratio of viable count 1:1, S4 group, 5.2 mg/g weight per day of gastric lavage protein powder+10 8 CFU/g weight of probiotics), complex bacterium group 2 (BNCC 192198 +bl21 group, ratio of viable count 1:1, total amount of gastric lavage protein powder 5.2+38 CFU/g weight per day of probiotics).
(3) Animal modeling and intervention method:
And establishing a sports fatigue rat model by adopting a swimming sports mode. Prior to modeling, rats were trained for 3 days of adaptive swimming, 1 time a day, 30min a times a day. After the corresponding medicament is infused into the stomach, the rats are resting 60 min a day, then are independently put into a swimming pool (50 cm ×50 cm ×40 cm) with the water depth of 30 cm, the water temperature is 30 ℃, the weight of the rats is 5% of the body weight of the rats during the swimming exercise (except for a CTL group, each rat in all groups is swim with a lead block attached to the tail part of the rats), the rats swim 1a day, the swimming time is 150 min a week, and the rats rest on sunday. Training was continued for 5 weeks.
(4) After molding and administration, the protein digestibility of the rats was calculated by Kjeldahl method (Kjeldahl method for measuring crude protein content in samples (including intake of nitrogen, fecal nitrogen and urinary nitrogen; protein digestibility/% = [ intake of nitrogen (g/d) -fecal nitrogen (g/d) ]/intake of nitrogen/(g/d) ×100). To measure pepsin activity of rats, 24 h fasted treatment (water intake) was performed on rats first, after anesthesia with diethyl ether, stomach was exposed through a small incision below the midline of abdomen, and pylorus region was ligated 2 h after surgery, the stomach was removed, and surface blood traces were removed after centrifugation of stomach contents (3000 rpm, 15 min), supernatant was collected to measure pepsin activity).
As shown in fig. 1 and 2, compared with the control group, the protein digestibility of the rats in the model group is obviously reduced, but after the intervention of probiotics in each group, the protein digestibility is improved to different degrees, and especially the protein digestibility of the S4 group is higher, which indicates that the composite probiotics related to the invention can improve the intestinal microenvironment and enhance the integrity of intestinal walls, thereby improving the digestion and absorption efficiency of proteins. The reduced digestibility of proteins means that the body is unable to efficiently utilize the ingested proteins, which may lead to insufficient energy metabolism and waste of nutrients. Conversely, when digestibility increases, the body can break down and absorb proteins more effectively, thereby promoting healthier metabolic processes.
Furthermore, the results of the pepsin activity test showed that: the pepsin activity of the model group is obviously reduced compared with the control group, but the enzyme activity is reversed after the intervention of probiotics in each group, and the effect of the S4 group is more obvious. Changes in pepsin activity directly affect the preliminary breakdown of proteins, a key step in the overall digestion process. This indicates that the complex probiotics according to the invention are capable of reversing the decline of pepsin activity in tired rats, and also demonstrates the importance of regulating digestive enzyme activity in improving the digestion efficiency of proteins.
(5) Behavioral evaluation:
After the molding and the bacteria administration are finished, 6 of the rats in each group are subjected to a negative gravity exhaustion test (the process is the same as (3), the exhaustion swimming time is the time from the beginning of swimming to the presentation of exhaustion, the exhaustion time is determined as the loss of coordinated movement and the failure to return to the water surface within 10 seconds), and the exhaustion time is recorded for analysis.
As shown in fig. 3, compared with the control group, the swimming time of the rats in the model group shows a significant decrease, and after the intervention of probiotics in each group, the swimming time of the rats is improved to different degrees, especially in the S4 group, which indicates that the compound probiotics related to the invention can improve the physical strength and endurance of the rats.
(6) Sample collection:
After the molding and administration, the remaining 6 rats of each group were subjected to blood collection, liver collection or gastrocnemius collection to determine the biochemical parameters associated with fatigue.
(7) Determination and results of fatigue-related biochemical parameters:
(7.1) serum analysis: after the rats are sacrificed, 10% chloral hydrate solution is injected into the abdominal cavity for anesthesia (3 mL/kg body weight), blood is taken, collected into a centrifuge tube with anticoagulant, kept stand for 30 min, centrifuged for 20 min at 4 ℃ by 3500 r/min, serum is taken out of an EP tube, marked and stored in a refrigerator at-80 ℃ for testing. Biochemical parameters including Blood Lactate (BL), lactate Dehydrogenase (LDH), blood Urease (BUN), glucose, free Fatty Acid (FFA) levels, and Creatine Kinase (CK) activity were measured using the kit.
As shown in fig. 4-9, the serum lactate (BL), lactate Dehydrogenase (LDH), serum urease (BUN), free Fatty Acid (FFA) levels and Creatine Kinase (CK) activities were abnormally increased and glucose levels were significantly decreased in the model group compared to the control group, but this was reversed after each probiotic intervention, and the S4 group effect was more remarkable in particular.
Elevation of blood lactate and lactate dehydrogenase is often indicative of increased tissue hypoxia and anaerobic metabolism, and the observation of these elevated indicators in the model set may indicate imbalance in metabolic stress and energy production. A significant decrease in post-probiotic intervention index may reflect an improvement in metabolic status and an increase in cellular respiration efficiency. An increase in blood urease may be indicative of a protein metabolic disorder and/or impaired renal function, while an increase in free fatty acid levels may reflect an increase in fat metabolism. These changes indicate that the energy metabolism of the rats in the model group is abnormal. Normalization of these indicators after probiotic intervention indicated restoration of metabolic stability. The increase in creatine kinase activity is often associated with muscle injury or stress, which may indicate that the muscle tissue of rats in the model group is damaged or stressed to some extent, and that the decrease in creatine kinase activity following probiotic intervention may reflect an improvement in muscle tissue status and a restoration in cell integrity. In addition, glucose is the primary energy source, and a decrease in its level may indicate an insufficient energy supply or a disturbed glucose metabolism, and a restoration of glucose levels after probiotic intervention may indicate a normalization of glucose metabolism and an improvement in energy balance.
(7.2) Determination of hepatic glycogen and myoglycogen: liver tissue and gastrocnemius muscle were harvested, 10% homogenate was prepared with physiological saline at 4 ℃ and Liver Glycogen (LG) and Myoglycogen (MG) levels were analyzed using the kit.
The results are shown in figures 10-11, where the liver glycogen and myoglycogen levels were significantly reduced in rats in the model group compared to the control group, but recovery was obtained after probiotic intervention and the S4 group had the best effect. Hepatic glycogen and myoglycogen are important forms of energy reserves in the body, and the decrease in these levels observed in rats in the model group may reflect depletion of energy reserves, possibly due to metabolic stress or increased energy demand. This decrease may lead to an insufficient energy supply, affecting the overall health and fitness of the rat. Recovery of liver glycogen and muscle glycogen levels following probiotic intervention suggests that probiotics may indirectly affect energy metabolism and reserves by improving intestinal health and nutrient absorption. This recovery may be due to improved absorption and utilization of nutrients, thereby increasing energy reserves. Liver glycogen and muscle glycogen are key energy sources for exercise of high intensity and long-term endurance activity, and their level restoration may contribute to improvement of physical performance and acceleration of the restoration process.
(7.3) Antioxidant Capacity analysis: reduction of oxidative stress and enhancement of the antioxidant capacity of cells are critical to maintaining muscle function and promoting muscle recovery. The kit is used to detect the content or activity of Reactive Oxygen Species (ROS), nitric Oxide (NO), malondialdehyde (MDA) in serum and gastrocnemius.
As shown in fig. 12-16, the serum and gastrocnemius levels of active oxygen, malondialdehyde and gastrocnemius nitric oxide were abnormally elevated in rats in the model group compared to the control group, but various indexes were reversed to different degrees after probiotic intervention, and especially the S4 group effect was more prominent.
The increase in active oxygen is generally associated with oxidative stress, while malondialdehyde is an important marker of lipid peroxidation. The elevation of these indicators observed in model rats may indicate an increase in oxidative stress and damage to cell membranes, which may negatively affect cell function, leading to cell metabolic disorders and tissue damage. Nitric oxide is an important signaling molecule, but abnormal increases in its levels may be associated with inflammatory responses and cellular injury, and increases in nitric oxide levels in the model set may reflect increases in inflammatory status and oxidative stress. The restoration of these indicators after the intervention of the probiotic S4 group indicates that the probiotics related to the invention can protect cells from injury by reducing oxidative stress and improving the antioxidant capacity of the cells.
The applicant states that the technical solution of the present invention is illustrated by the above embodiments, but the present invention is not limited to the above embodiments, i.e. it does not mean that the present invention must be implemented by the above embodiments. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (7)
1. The probiotics for resisting sports fatigue is characterized in that the strain in the probiotics consists of Pediococcus ACIDILACTICI PA strain with the preservation number of CGMCC No. 18798 and Bifidobacterium longum Bifidobacterium longum BL strain with the preservation number of CGMCC No. 10452;
The ratio of the viable count of the PA53 strain to the BL21 strain is 1:5-5:1, and the total viable count in the probiotic is not lower than 5X 10 9 CFU/mL or 5X 10 9 CFU/g.
2. The exercise-fatigue resistant probiotic according to claim 1, further comprising a lyoprotectant;
the freeze-drying protective agent comprises any one or a combination of at least two of skim milk, gelatin, dextrin, acacia, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.
3. The exercise fatigue resistant probiotic according to claim 1, further comprising an auxiliary additive;
the auxiliary additive comprises any one or a combination of at least two of fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, soybean oligosaccharide, inulin, spirulina, arthrospira, coriolus versicolor polysaccharide, stachyose, polydextrose, alpha-lactalbumin or lactoferrin.
4. The exercise-fatigue-resistant probiotic according to claim 1, wherein the formulation of the probiotic comprises a lyophilized powder, a capsule, a tablet or a granule.
5. Use of a probiotic according to any one of claims 1 to 4 for the preparation of a food, a health product or a pharmaceutical product for preventing and/or alleviating sports fatigue.
6. The use according to claim 5, wherein the food, health product or pharmaceutical product further comprises an adjuvant;
The auxiliary materials are selected from any one or a combination of at least two of filler, adhesive, wetting agent, disintegrating agent, emulsifying agent, cosolvent, solubilizer, osmotic pressure regulator, colorant, pH regulator, antioxidant, antibacterial agent or buffering agent.
7. Use of a probiotic according to any one of claims 1 to 4 for the preparation of a product with improved protein digestion or absorption capacity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410405247.5A CN117987333B (en) | 2024-04-07 | 2024-04-07 | Composite probiotics for relieving sports fatigue and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410405247.5A CN117987333B (en) | 2024-04-07 | 2024-04-07 | Composite probiotics for relieving sports fatigue and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117987333A CN117987333A (en) | 2024-05-07 |
| CN117987333B true CN117987333B (en) | 2024-06-07 |
Family
ID=90893684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410405247.5A Active CN117987333B (en) | 2024-04-07 | 2024-04-07 | Composite probiotics for relieving sports fatigue and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117987333B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104894005A (en) * | 2015-04-30 | 2015-09-09 | 江苏紫石微康生物科技有限公司 | Extracellular polysaccharide high-yielding lactic acid bacterium BL21, and preparation method and application thereof |
| CN113278538A (en) * | 2021-03-01 | 2021-08-20 | 漯河微康生物科技有限公司 | Lactic acid bacteria with high folic acid yield, preparation method and application thereof |
| WO2023079276A1 (en) * | 2021-11-03 | 2023-05-11 | Iiaa Limited | Compositions comprising probiotic and postbiotic strains of bacteria |
-
2024
- 2024-04-07 CN CN202410405247.5A patent/CN117987333B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104894005A (en) * | 2015-04-30 | 2015-09-09 | 江苏紫石微康生物科技有限公司 | Extracellular polysaccharide high-yielding lactic acid bacterium BL21, and preparation method and application thereof |
| CN113278538A (en) * | 2021-03-01 | 2021-08-20 | 漯河微康生物科技有限公司 | Lactic acid bacteria with high folic acid yield, preparation method and application thereof |
| WO2023079276A1 (en) * | 2021-11-03 | 2023-05-11 | Iiaa Limited | Compositions comprising probiotic and postbiotic strains of bacteria |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117987333A (en) | 2024-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11197901B2 (en) | Active substance of Lactobacillus paracasei GKS6, a composition comprising thereof and its use for promoting longevity | |
| CN111662850B (en) | Lactobacillus paracasei capable of relieving alcoholic intestinal injury and application thereof | |
| CN105567586A (en) | Lactobacillus plantarum having anti-diabetic function and application thereof | |
| WO2020063646A1 (en) | Strain for preventing and treating metabolic diseases and use thereof | |
| CN113583903A (en) | Microbial composition for preventing or treating type II diabetes and preparation method and application thereof | |
| US20220143114A1 (en) | Active substance of lactobacillus plantarum gkm3, a composition comprising thereof and its use for promoting longevity | |
| CN114921363A (en) | Composite probiotics for inhibiting fat accumulation and application thereof | |
| CN116042477A (en) | Lactobacillus plantarum J26 composition, preparation method and application thereof in weight-losing products | |
| CN117778279B (en) | Probiotic agent for degrading ethanol and application thereof | |
| CN116855413B (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN112574924B (en) | Bacillus subtilis strain, microecological preparation and application thereof | |
| CN117987333B (en) | Composite probiotics for relieving sports fatigue and application thereof | |
| KR100769299B1 (en) | Lactobacillus fermentum and dairy products and health-promoting food containing the same | |
| CN116064313A (en) | Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue | |
| Sasmita et al. | Potential use of fermented dangke cheese to improve glycemic control in rats fed with a high-fat glucose diet and propylthiouracil | |
| CN113261592A (en) | Probiotics goat milk powder and preparation method thereof | |
| CN116606761B (en) | Bifidobacterium animalis subspecies BLa19 capable of relieving rheumatoid arthritis and application thereof | |
| CN116396891B (en) | Probiotic composition of lactobacillus acidophilus LA-G80 and bifidobacterium bifidum BB-G90 and application thereof in liver protection | |
| CN117778277B (en) | Composite probiotics for promoting intestinal iron ion absorption and application thereof | |
| CN117025492B (en) | Streptococcus thermophilus JYST-81 for reducing obesity of pets and application thereof | |
| CN117050914B (en) | Acremonium muciniphilum and application thereof in improving GLP-1 secretion | |
| CN117384790B (en) | Pediococcus pentosaceus KS5 and application thereof in preparation of sleep-aiding drugs | |
| CN114668151B (en) | Application of bifidobacterium lactis SF-B21 in preparation of uric acid reducing products | |
| Murtia et al. | 2403 Intestinal Enzymes and Lactid Acid Bacteria of Red Tilapia (Oreochromis sp.) Fed Black Soldier Fly (Hermetia illucens) Larvae and Probiotics | |
| CN116162557A (en) | A strain of Saccharomyces cerevisiae, chinese medicinal microecological preparation for preventing and treating ruminant diarrhea, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |